Amplia Therapeutics Says No Toxicity Concerns Identified Regarding Narmafotinib Drug Candidate After Recruitment Halt in Clinical Trial

MT Newswires Live

Apr 08

Amplia Therapeutics (ASX:ATX) said no toxicity concerns were identified regarding its drug candidate narmafotinib, and its Chief Executive Christopher Burns said the results do not impact the firm's plans to explore combinations of narmafotinib, according to a Wednesday Australian bourse filing.

It halted further recruitment in the Amplicity clinical trial following three dose-limiting toxicities related to the chemotherapy regimen modified Folfirinox.

The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2625990188"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625990188\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625990188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 14:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625990188","market":"sg","top_or_hot":-1,"title":"Amplia Therapeutics Says No Toxicity Concerns Identified Regarding Narmafotinib Drug Candidate After Recruitment Halt in Clinical Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said no toxicity concerns were identified regarding its drug candidate narmafotinib, and its Chief Executive Christopher Burns said the results do not impact the firm's plans to explore combinations of narmafotinib, according to a Wednesday Australian bourse filing.</p><p>It halted further recruitment in the Amplicity clinical trial following three dose-limiting toxicities related to the chemotherapy regimen modified Folfirinox.</p><p>The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amplia Therapeutics Says No Toxicity Concerns Identified Regarding Narmafotinib Drug Candidate After Recruitment Halt in Clinical Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmplia Therapeutics Says No Toxicity Concerns Identified Regarding Narmafotinib Drug Candidate After Recruitment Halt in Clinical Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-08 14:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ATX.AU\">Amplia Therapeutics</a> (ASX:ATX) said no toxicity concerns were identified regarding its drug candidate narmafotinib, and its Chief Executive Christopher Burns said the results do not impact the firm's plans to explore combinations of narmafotinib, according to a Wednesday Australian bourse filing.</p><p>It halted further recruitment in the Amplicity clinical trial following three dose-limiting toxicities related to the chemotherapy regimen modified Folfirinox.</p><p>The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATX.AU","symbol_name":"AMPLIA THERAPEUTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625990188","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625990188","pubTimestamp":1775629615,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amplia Therapeutics  said no toxicity concerns were identified regarding its drug candidate narmafotinib, and its Chief Executive Christopher Burns said the results do not impact the firm's plans to explore combinations of narmafotinib, according to a Wednesday Australian bourse filing.It halted further recruitment in the Amplicity clinical trial following three dose-limiting toxicities related to the chemotherapy regimen modified Folfirinox.The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATX.AU":"AMPLIA THERAPEUTICS LTD","BK4007":"制药","LENZ":"Therapeutics","BK4539":"次新股","BK4139":"生物科技","BK7067":"生物科技"},"translate_title":"Amplia Therapeutics表示，在临床试验招募停止后，没有发现Narmafotinib候选药物的毒性问题","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ATX.AU":1},"content_text":"Amplia Therapeutics (ASX:ATX) said no toxicity concerns were identified regarding its drug candidate narmafotinib, and its Chief Executive Christopher Burns said the results do not impact the firm's plans to explore combinations of narmafotinib, according to a Wednesday Australian bourse filing.It halted further recruitment in the Amplicity clinical trial following three dose-limiting toxicities related to the chemotherapy regimen modified Folfirinox.The remaining five patients will remain on study and continue to receive the combination with continued safety monitoring.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}